Disease summary PF-ILD along with NT-proBNP is a dubious disease in the area of infectious respiratory digestive and endocrine disorders, with clinical performance being complex and often involving multi-system fatigue. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostic and treatment programs. Treatment and management of PF-ILD associated with NT-proBNP require individualized development, typically including multidimensional management of drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of therapeutic-focused, immune-regulated therapy, and precision medicine, significant improvements have been made in many previously difficult-to-treat infectious respiratory digestive and endocrine disorders.
The platform serves the China International Medical Service System, which combines domestic and foreign authoritative teams of experts in the field of infectious respiratory digestive and endocrine secretion to provide the following services to patients: 1. Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by the team of experts; 2. Interviews in China: Arrangements with authoritative experts for face-to-face diagnosis, development of personalized treatment programs; 3.
Full-service: One-stop services: Medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: Establishment of a chronic disease management file, continuous monitoring of changes in disease and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.